Motley Fool  Jul 13  Comment 
Which stock wins in a battle between a small, beaten-down biotech and an established major drugmaker?
Motley Fool  Jul 9  Comment 
Both of these pharmaceutical giants face competitive threats, but both have strong pipelines.
FiercePharma  Jun 28  Comment 
Eli Lilly’s Taltz is already up against Novartis’ immunology blockbuster Cosentyx in psoriasis and psoriatic arthritis. Now, Lilly looks poised to challenge the Swiss drugmaker in a third indication, too.
MarketWatch  Jun 28  Comment 
Eli Lilly and Co. announced positive results Thursday in a midstage trial of a treatment for Ankylosing Spondylitis, an inflammatory disease that can cause some of the vertebrae in the spine to fuse. The company said the trial of Taltz met its...
GenEng News  Jun 25  Comment 
Merrimack Pharmaceuticals said today it will cease development of its pancreatic cancer candidate MM-141 (istiratumab) following its failure in a Phase II trial. MM-141 missed its primary and secondary endpoints in the Phase II CARRIE trial (...
The Economic Times  Jun 24  Comment 
The U.S. District Court for the Southern District of Indiana ruled in favor of Lilly, a release from the US drug maker said.
The Hindu Business Line  Jun 20  Comment 
 Unichem Laboratories has entered into a settlement pact with pharma major Eli Lilly & Company and ICOS Corporation for resolving their patent lit
The Hindu Business Line  Jun 19  Comment 
Zydus Cadila has received approval from the US health regulator to market Tadalafil tablets, used for treating erectile dysfunction, in the American

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki